Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Issue 2 (1st February 2016)

• Record Type: Journal Article
• Authors: Yabe, Daisuke; Seino, Yutaka
• Is Part Of: Expert opinion on drug safety. Volume 15:Issue 2(2016)
• Page Start: 249
• Page End: 264
• Publication Date: 2016-02-01
• Subjects: Alogliptin -- dipeptidyl peptidase-4 inhibitors -- safety -- tolerability -- type 2 diabetes; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1517/14740338.2016.1125467
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Dipeptidyl peptidase-4 (DPP-4) inhibitors such as alogliptin are becoming more widely established as treatment options for patients with type 2 diabetes (T2DM) because of their ability to improve glycemic control without increasing the risk of hypoglycemia or weight gain. New therapies with improved safety profiles are needed, especially because of the chronic and progressive nature of T2DM. Areas covered : In this article, the overall safety and tolerability of alogliptin are evaluated based upon a review of the literature. In particular, adverse events (AEs) that have been of interest for the DPP-4 class of drugs, such as the risk of major cardiovascular (CV) events and acute pancreatitis, will be investigated in detail. Expert opinion : Alogliptin is generally well-tolerated in a broad range of patient populations including different ethnic groups and the elderly. In the pivotal EXAMINE clinical trial, alogliptin was found not to be associated with an increased risk of major CV events or acute pancreatitis/pancreatic cancer.